Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elan Eyes Tysabri sBLA For Crohn’s In U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

Biologic could be positioned as a monotherapy.

You may also be interested in...



1,000 Physicians, 4,500 Patients Enrolled In Tysabri TOUCH Program

Elan reports early data on uptake of the MS therapy, but says it is too early to tell how many enrollees will convert to patients treated.

1,000 Physicians, 4,500 Patients Enrolled In Tysabri TOUCH Program

Elan reports early data on uptake of the MS therapy, but says it is too early to tell how many enrollees will convert to patients treated.

Tysabri Re-Launches In U.S. Through Single Distributor

Biogen Idec/Elan's multiple sclerosis therapy Tysabri is available in the U.S. through a single distributor: AmerisourceBergen Specialty Group division ICS

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel